Mutation analysis of NRAS/KRAS/BRAF, PIK3CA and CSF-1R in plasma has been applied in a phase 2 clinical trial to assess response to a mitogen-activated protein kinase (MEK) inhibitor (refametinib) in advanced HCC patients [49]. This evidence concerns the gene NRAS and hepatocellular carcinoma.